NCT05414500View on ClinicalTrials.gov

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

PHASE1RecruitingINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

July 31, 2026

Conditions

Cutaneous T Cell LymphomaMycosis Fungoides

Interventions

DRUG

Mogamulizumab

Administered IV

DRUG

Brentuximab vedotin

Administered IV

Trial Locations (1)

35233

RECRUITING

University of Alabama at Birmingham, Birmingham

Sponsors

Collaborators (1)

Kyowa Kirin, Inc.

All Listed Sponsors

collaborator

Seagen Inc.

INDUSTRY

collaborator

Kyowa Kirin, Inc.

INDUSTRY

lead

University of Alabama at Birmingham

OTHER